학술논문
PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors
Document Type
article
Author
Henning Plage; Kira Furlano; Sebastian Hofbauer; Sarah Weinberger; Bernhard Ralla; Antonia Franz; Annika Fendler; Michela de Martino; Florian Roßner; Sefer Elezkurtaj; Martina Kluth; Maximilian Lennartz; Niclas C. Blessin; Andreas H. Marx; Henrik Samtleben; Margit Fisch; Michael Rink; Marcin Slojewski; Krystian Kaczmarek; Thorsten Ecke; Steffen Hallmann; Stefan Koch; Nico Adamini; Henrik Zecha; Sarah Minner; Ronald Simon; Guido Sauter; Joachim Weischenfeldt; Tobias Klatte; Thorsten Schlomm; David Horst; Simon Schallenberg
Source
BMC Urology, Vol 24, Iss 1, Pp 1-9 (2024)
Subject
Language
English
ISSN
1471-2490
Abstract
Abstract Background A high level of PD-L1 expression is the most relevant predictive parameter for response to immune checkpoint inhibitor (CPI) therapy in urinary bladder cancer. Existing data on the relationship between PD-L1 expression and the natural course of disease are controversial and sparse. Methods To expand our understanding of the relationship between PD-L1 expression and parameters of cancer aggressiveness, PD-L1 was analyzed on tissue microarrays containing 2710 urothelial bladder carcinomas including 512 patients with follow-up data who underwent radical cystectomy and follow-up therapies in the pre-immune checkpoint inhibitor therapy era. Results Tumor cell positivity in ≥10% of cells were seen in 513 (20%) and an immune cell positivity occurred in 872 (34%) of 2566 interpretable cancers. PD-L1 positivity in tumor cells increased from pTaG2 low grade (0.9% positive) to pTaG3 high grade (4.1%; p = 0.0255) and was even higher in muscle-invasive (pT2–4) carcinomas (29.3%; p